Cargando…
Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma
Immune checkpoint inhibitors have demonstrated promising efficacy and tolerable safety for advanced malignancies. However, a proportion of patients who had received immunotherapy may experience hyperprogressive disease and a resultant poor prognosis. Here, we report a patient with advanced esophagea...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722699/ https://www.ncbi.nlm.nih.gov/pubmed/33151119 http://dx.doi.org/10.1080/15384047.2020.1834319 |